Founder connected pharmaceutical direction
One pharmaceutical thesis. Distinct operating states.
A medicines signal creates more value when intelligence, development and delivery inform one another. PHARMORIS is NEUVIOR’s product priority; VARUNÉ Labs is its predevelopment programme for medicines and formulation research.
The public relationship map
Understand the medicine. Develop the opportunity. Build the route to delivery.
NEUVIOR is the current pharmaceutical company. PHARMORIS is its immediate product priority, built around the work required to move medicines evidence into a human decision and accountable action.
VARUNÉ Labs is a predevelopment programme founded by Varun Sharma and operated by NEUVIOR PHARMACEUTICALS LTD (SC857853). It explores medicines, formulations, generics, skincare, fragrance research and longer range manufacturing planning. It is not a separate legal company or a current laboratory or manufacturing operation.
NEUVIOR
The company that holds the medicines systems thesis, commercial direction, public record and the capability building sequence.
Current pharmaceutical companyPHARMORIS
A human governed medicines operations system designed to connect evidence, ActionCases, decisions, delivery and ValueReview.
Current product priorityVARUNÉ Labs
A predevelopment programme operated by NEUVIOR, exploring medicines, formulations, personal care and future manufacturing planning.
Predevelopment programmeThe capability chain
A better future for medicine needs more than a single product.
A medicines opportunity can be visible through NEUVIOR and PHARMORIS while the development pathway, supply resilience or manufacturing capacity remains a separate problem. The founder thesis connects the questions, while keeping each entity, right, asset and operating claim distinct.
The sequence is disciplined: prove what the customer needs, identify which entity should own the work, build the scientific and operating capability, then add assets only when quality, approvals and economics support them.
Understand
Use PHARMORIS to make evidence, uncertainty, ownership and the decision path visible.
Medicines intelligence · current priorityDevelop
Explore formulation, research and partner capability through the NEUVIOR operated VARUNÉ Labs predevelopment programme.
Predevelopment programmeDeliver
Consider manufacturing and supply routes under the entity that can lawfully hold the rights, licences, quality systems and capital.
Future decision gateThe one year target operating model
A fully formed operating model before unnecessary scale.
The next stage is not about adding logos or announcing divisions. NEUVIOR’s target is one stronger commercial engine, one evidence system, a clear scientific direction, an international relationship network and explicit ownership of every build priority.
For NEUVIOR, that means a stronger PHARMORIS evaluation route, investor grade company information and active public thinking. VARUNÉ Labs adds a predevelopment research direction under NEUVIOR’s operation; actual programmes, facilities and manufacturing require their own evidence, rights and approvals.
Commercial system
A repeatable path from a buyer problem to a bounded PHARMORIS evaluation and evidence backed next decision.
Scientific system
A coherent medicines, formulation and development agenda supported by the right experts, sources and projects.
Company system
Clear leadership, capital priorities, public communications, locations, partners and proof in one operating narrative.
- Podcast appearance. AI Ethics Now / University of Warwick IATL. AI and Accountability: When Does a Suggestion Become a Decision?. 23 August 2026.
- Contributed analysis. Pharmaphorum. Approval is not access: Pilots' real test is implementation. 18 August 2026.
- Contributed opinion. TechRadar Pro. Five questions to test whether an AI stack is truly under your control. 11 August 2026.
- Founder commentary. ET Pharma. India’s pharma quality reset will be won after the inspector leaves. 4 August 2026.
- NEUVIOR analysis. NEUVIOR Founder Reflections. From invention to adoption: the work between. 3 August 2026.
- NEUVIOR analysis. NEUVIOR Founder Reflections. A trade deal is not a patient pathway. 3 August 2026.
- NEUVIOR analysis. NEUVIOR Insights. NHS digital programmes do not fail on dashboards. They fail on deployment. 20 March 2026.
- Founder viewpoint. Pharmaceutical Technology. Why the India UK trade deal now needs a five gate implementation ledger. 28 July 2026.
- Release derived reporting. TheBusinessDesk.com. NEUVIOR company support coverage. 19 May 2026.
- Founder commentary. Startups Magazine. What my dad's corner shop taught me. 6 May 2026.
- Expert commentary. Manufacturing Chemist. NICE approval is not enough: why the UK's next medicines challenge is operational delivery. 4 June 2026.
- Founder commentary. PharmaTimes. How we roll. 10 June 2026.
- Founder commentary. BusinessCloud. Why neurodivergent founders can excel at building complex systems. 18 March 2026.
- Partner announcement. Biorenewables Development Centre. NEUVIOR research record. 20 April 2026.
Classified public record
IDEAS + PUBLIC RECORD
See how the company thesis becomes an operating sequence.
Start with the medicines problem, follow the founder’s case for connected intelligence and development, then inspect the public record behind the company.
AI and Accountability: When Does a Suggestion Become a Decision?
Varun Sharma joins AI Ethics Now to examine false confidence, human responsibility and the point where AI assisted suggestions become accountable decisions.
Listen to the AI Ethics Now conversationApproval is not access: Pilots' real test is implementation
In pharmaphorum, Varun Sharma argues that medicines access pilots should measure the full chain from recommendation to funded delivery and outcomes.
Read why approval is not accessFive questions to test whether an AI stack is truly under your control
In TechRadar Pro, Varun Sharma sets out five tests for enterprise AI control across provenance, infrastructure, legal authority and safe exit.
Test whether an AI stack is truly controlled
NEUVIOR Insights and After Publication reflections are company or founder analysis. Publisher records evidence publication, not endorsement, adoption, product readiness, savings or clinical outcomes.
Make the next step useful
Bring the problem that needs a clearer decision.
Tell us what is stuck, what decision you need to make and what a better outcome would change. We will connect you to the most relevant NEUVIOR, PHARMORIS, media or investor route.